Shenzhen Weiguang Biological Products Co Ltd (002880) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shenzhen Weiguang Biological Products Co Ltd (002880) has a cash flow conversion efficiency ratio of 0.022x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥51.60 Million ≈ $7.55 Million USD) by net assets (CN¥2.36 Billion ≈ $344.86 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Shenzhen Weiguang Biological Products Co for the company's overall valuation and market capitalisation.
Shenzhen Weiguang Biological Products Co Ltd - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Shenzhen Weiguang Biological Products Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Shenzhen Weiguang Biological Products Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shenzhen Weiguang Biological Products Co Ltd ranked by their cash flow conversion efficiency. Explore 002880 cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nanjing Canatal Data Centre Environmental Tech Co Ltd Class A
SHG:603912
|
0.024x |
|
Huarong Chemical Co. Ltd.
SHE:301256
|
N/A |
|
Shandong Rike Chemical
SHE:300214
|
0.022x |
|
Man Industries (India) Limited
NSE:MANINDS
|
-0.032x |
|
Beijing Navigation Control Technology Co. Ltd.
SHG:688282
|
N/A |
|
Yangzhou Seashine New Materials Co
SHE:300885
|
0.030x |
|
Viglacera Corp JSC
VN:VGC
|
0.042x |
|
Suzhou Sunmun Technology Co Ltd
SHE:300522
|
0.052x |
Annual Cash Flow Conversion Efficiency for Shenzhen Weiguang Biological Products Co Ltd (2012–2025)
The table below shows the annual cash flow conversion efficiency of Shenzhen Weiguang Biological Products Co Ltd from 2012 to 2025. View Shenzhen Weiguang Biological Products Co share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥2.45 Billion ≈ $357.80 Million |
CN¥263.18 Million ≈ $38.51 Million |
0.108x | +35.89% |
| 2024-12-31 | CN¥2.24 Billion ≈ $328.40 Million |
CN¥177.77 Million ≈ $26.01 Million |
0.079x | -59.28% |
| 2023-12-31 | CN¥2.05 Billion ≈ $299.34 Million |
CN¥397.94 Million ≈ $58.23 Million |
0.195x | +30198.49% |
| 2022-12-31 | CN¥1.87 Billion ≈ $273.28 Million |
CN¥1.20 Million ≈ $175.46K |
0.001x | -99.53% |
| 2021-12-31 | CN¥1.79 Billion ≈ $261.68 Million |
CN¥246.89 Million ≈ $36.13 Million |
0.138x | -26.25% |
| 2020-12-31 | CN¥1.62 Billion ≈ $237.61 Million |
CN¥303.96 Million ≈ $44.48 Million |
0.187x | +46.04% |
| 2019-12-31 | CN¥1.45 Billion ≈ $212.00 Million |
CN¥185.70 Million ≈ $27.17 Million |
0.128x | +68.15% |
| 2018-12-31 | CN¥1.31 Billion ≈ $191.08 Million |
CN¥99.54 Million ≈ $14.57 Million |
0.076x | +220.52% |
| 2017-12-31 | CN¥1.20 Billion ≈ $176.06 Million |
CN¥28.61 Million ≈ $4.19 Million |
0.024x | -90.47% |
| 2016-12-31 | CN¥506.44 Million ≈ $74.11 Million |
CN¥126.41 Million ≈ $18.50 Million |
0.250x | -34.53% |
| 2015-12-31 | CN¥393.71 Million ≈ $57.61 Million |
CN¥150.09 Million ≈ $21.96 Million |
0.381x | -12.24% |
| 2014-12-31 | CN¥308.86 Million ≈ $45.20 Million |
CN¥134.17 Million ≈ $19.63 Million |
0.434x | +364.69% |
| 2013-12-31 | CN¥223.88 Million ≈ $32.76 Million |
CN¥20.93 Million ≈ $3.06 Million |
0.093x | -89.11% |
| 2012-12-31 | CN¥135.00 Million ≈ $19.76 Million |
CN¥115.88 Million ≈ $16.96 Million |
0.858x | -- |
About Shenzhen Weiguang Biological Products Co Ltd
Shenzhen Weiguang Biological Products Co., Ltd. engages in the research, development, production, and sale of blood products in China. The company offers human factor VIII, human immunoglobulin (PH4), human rabies immunoglobulin, human tetanus immunoglobulin, human hepatitis B immunoglobulin, human albumin, human histaglobulin, human firbrinogen, human immunoglobulin for intravenous injection fre… Read more